您所在的位置:
作者:Sandra Li
单位:Monash University

摘要

Purpose: Ischaemic stroke remains a major cause of death and disability worldwide. Existing therapies do not target neuroprotection or regeneration. Neural stem cells (NSCs) have unique neuroregenerative, anti-inflammatory and neuroprotective properties. However, NSCs have limited migratory ability and experience low survivability within ischaemic environments. This study aimed to identify stroke induced chemokine signals, then genetically overexpress corresponding chemokine receptors in iPSC-NSCs to enhance their therapeutic efficacy.

 

Methodology: Photothrombotic (PT) stroke was induced in postnatal day (PND) 10 rat pups. Infarcted brain tissue was collected 24-hours later for chemokine analysis. Immunocytochemistry and qPCR were used to validate iPSC to NSC differentiation. Overexpression of CCR5 in iPSC-NSCs via lentiviral transduction was validated with flow cytometry and Boyden chamber. Therapeutic efficacy of genetically modified NSCs was compared with naïve NSCs in our PT model. Cells were administered at 24-hours post-stroke via an intra-arterial cannula into the carotid artery. A dose escalation study (1x106, 2.5x106 and 5x106 cells in 100µL PBS) was conducted. Animals were sacrificed 24-hours post-administration for migration and histological analyses, 3-days and 40-days for behavioural analyses.

 

Results: iPSC-NSCs maintained stemness up to passage 10. Chemokine analysis revealed upregulation of CCL3, the target ligand for CCR5. Lentiviral overexpression of CCR5 in NSCs was successful with 80% transduction efficiency. Preliminary Boyden chamber assays demonstrated increased migratory ability of CCR5-NSCs compared to naïve NSCs. Intra-arterial cell delivery was successfully optimised, with cell doses up to 5x106 well-tolerated without mortality. Preliminary data demonstrates successful migration of CCR5-NSCs to the ischaemic area. Ongoing work will investigate effect of dose-escalation and impact on infarct volume, microglial response and neuronal loss.

 

Conclusion: iPSC-NSCs with genetically enhanced migratory capacity has the potential to be a regenerative and neuroprotective adjunct therapy for ischaemic stroke. Intra-arterial delivery aligns well with current clinical treatment workflows, improving the translatability of this therapy.


相关会议

更多
“医”路携手,“药”有作为一基层抗感染系列学术研讨会(3)
2026-11-30
北京
重庆市医师协会器官移植医师分会2026年学术年会
2026-11-30
待定

相关直播

更多
第八届上海国际癌症大会
2026-06-03
上海静安英迪格酒店
观看回放
产前咨询
2026-09-01
产前咨询
观看回放
冠心病及腔内影像生理学规范诊疗系列课程:左心室血栓的诊疗新进展
2026-11-17
阜外医院冠心病一病区
观看回放

最新视频

更多
糖尿病分型诊断中国专家共识解读
徐静
西安交通大学第二附属医院
李宗恩授课
李宗恩
病例分享
王攀霞
喀什市人民医院
高脂血症与急性胰腺炎
高静
新疆医科大学第五附属医院